

January 27, 2022

National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th Floor, Plot No: C/1, G - Block, Bandra – Kurla Complex, Bandra (East), Mumbai - 400 051 NSE Symbol: ORCPHARMA	BSE Limited Corporate Relationship Department 1st floor, New Trading Ring Rotunda Building, P J Towers Dalal Street, Fort Mumbai - 400 001 BSE Code: 524372
---	---


Sub: Reconciliation of Share Capital Audit

Dear Sir/Madam

We enclose a certificate from Company Secretary in Practice confirming the reconciliation of share capital audit undertaken for the purpose of reconciliation of the total admitted capital with both the depositories and the total issued and listed capital as on December 31, 2021.

Kindly take the above on your records.

Thanking you,

Yours faithfully,
Orchid Pharma Limited
313, Valluvarkottam
High Road
Nungambakkam
Chennai - 600 034

Nikita K
Company Secretary

Encl: a/a



RECONCILIATION OF SHARE CAPITAL AUDIT REPORT
(As per Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018)

To
The Board of Directors
M/s Orchid Pharma Limited
"Orchid Towers", 313, Valluvar Kottam High Road,
Nungambakkam, Chennai-600 034, Tamil Nadu, India.

1. For the Quarter Ended	31 st December, 2021	
2. ISIN No.	INE191A01027	
3. Face Value	INR.10/-	
4. Name & CIN of the Company	M/s Orchid Pharma Limited CIN: L24222TN1992PLC022994	
5. Registered Office Address	"Orchid Towers", 313, Valluvar Kottam High Road, Nungambakkam, Chennai-600 034.	
6. Correspondence Address	"Orchid Towers", 313, Valluvar Kottam High Road, Nungambakkam, Chennai-600 034.	
7. Telephone & Fax Nos.	Tel No- 044-2821 1000, Fax No.-044-2821 1002	
8. E-Mail Address	corporate@orchidpharma.com	
9. Name of the Stock Exchanges where the Company's Securities are listed	BSE Limited National Stock Exchange of India Limited	
10. Issued Capital	<i>No. of Shares</i>	<i>% of Total Issued Capital</i>
	4,08,16,400	100.00
11. Listed Capital (Exchange wise)	BSE Limited :	4,08,16,400 100.00
	National Stock Exchange of India Limited:	4,08,16,400 100.00
12. Held in Dematerialized Form in NSDL		<i>% of Total Listed Capital</i>
	20,39,865	5.00
13. Held in Dematerialized Form in CDSL	3,87,72,986	94.99
14. Physical	3549	0.01
15. Total No. of Shares	4,08,16,400	100.00

Subramani
am Lalitha
Digitally signed by
Subramaniam Lalitha
Date: 2022.01.22
15:24:14 +05'30'



16. Reasons for difference if any, between (10&11), (10&15), (11&15):

Nil

17. Certify the details of changes in Share Capital during the Quarter under consideration:

Nil

18. Register of Members is updated (Yes/No) If not updated up to which date	Yes, 31 st December, 2021 N.A
--	---

19. Reference of previous quarter with regard to excess dematerialized shares, if any?

Not Applicable

20. Has the Company resolved the matter mentioned in point no. 19 above in the current quarter? If not, reason why?

Not Applicable

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:

Nil

22. Name, Telephone No & fax No. of the Compliance Officer.	Ms Nikita K Company Secretary and Compliance Officer Ph: 044-2824 4355, Fax: 044-2821 1002, Email id: nikitak@orchidpharma.com
23. Name, Address, Telephone No. of the Certifying Company Secretary.	Mrs S Lalitha Company Secretary in Practice FCS, C.P No: 2666 No.98/36, 2 nd Floor, Halls Road, Kilpauk, Chennai-600 010. Mobile No.: +91 99625 11540 E Mail id: lalitha.companysecretary@gmail.com
24. Appointment of Common agency for share Registry work.	M/s Abhipra Capital Limited Abhipra Complex, A-387, Dilkhush Industrial Area, GT Karnal Road, Azadpur, Delhi - 110033 Ph: 011 - 42390909/ 011 - 42390725 E Mail id: rta@abhipra.com ; info@abhipra.com Website: www.abhipra.com

Subramani
am Lalitha
Digitally signed by
Subramaniam Lalitha
Date: 2022.01.22
15:24:40 +05'30'



25. Any other detail that the auditor may like to provide. (e.g. BIFR Company, delisting from SE, change in Company name):
- i. The Deposit Agreement(s) dated November 02, 2005 entered into between the Company, Citibank, N.A. (Depository) and the Holders and Beneficial Owners of the GDRs have been terminated with effect from November 15, 2021 and 14,803 Global Depository Receipts (GDR's) of the Company have been delisted from the Luxembourg Stock Exchange with effect from the aforesaid date and further London Stock Exchange have confirmed that the aforesaid GDRs are cancelled from admission to trading on the London Stock Exchange with effect from November 15, 2021.

Date: 22nd January, 2022
Place: Chennai

**Subramani
am Lalitha** Digitally signed by
Subramaniam Lalitha
Date: 2022.01.22
15:25:02 +05'30'
CS Lalitha S
Company Secretary in Practice
M No.4464
C P No.2666
UDIN: F004464C002257726